- Cancer Patient Receives First Proton Therapy Treatment At University Of Florida Proton Therapy
A Cocoa Beach man with prostate cancer today (Aug. 14) became the first patient to undergo treatment at the new University of Florida Proton Therapy Institute, the first time the most advanced form of radiation therapy available has been offered in the Southeast. - Experimental RNA-based Drug Kills Prostate Cancer Cells Effectively And Safely
Acting as a genetic Trojan horse, an experimental RNA-based drug -- the first of its kind -- tricks its way into prostate cancer cells and then springs into action to destroy them, while leaving normal cells unarmed. - Focus Surgery, Inc. Receives FDA Approval For A Phase III Clinical Study Using HIFU
Focus Surgery, Inc. the developer of the Sonablate(R) 500, announced today that the Food and Drug Administration (FDA) granted the Sonablate(R) 500 a provisional Investigational Device Exemption (IDE), which will allow the device to be used in a multicenter clinical study to collect safety and efficacy data for final FDA approval. The clinical study will use High Intensity Focused Ultrasound (HIFU) for the treatment of low risk, localized (T1c/T2a) prostate cancer with the Sonablate(R) 500. - Altering Fatty Acid Levels In Diet May Reduce Prostate Cancer Growth Rate, UCLA Study Shows
UCLA researchers found that altering the fatty acid ratio found in the typical Western diet to include more omega-3 fatty acids and decrease the amount of omega-6 fatty acids may reduce prostate cancer tumor growth rates and PSA levels. - Spectrum Pharmaceuticals Announces Phase 2 Data For Ozarelix In Hormone-Dependent Prostate Cancer
Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced data from its Phase 2 trial with ozarelix for patients suffering from hormone-dependent prostate cancer. - Third Mobile Ablatherm-HIFU Device To Start Service In Germany; Ongoing Growth
EDAP TMS S.A. (Nasdaq: EDAP) the global leader in High Intensity Focused Ultrasound treatment of prostate cancer will be placing a third mobilized Ablatherm-HIFU device early September to serve the growing needs of the German market under its innovative revenue-per-procedure model. Ablatherm-HIFU is recognized as the most advanced HIFU device available for localized prostate cancer with more than 10 years of treatment experience. - Ablatherm-HIFU Launches RPP Service At First Site In Portugal
EDAP TMS S.A. (Nasdaq: EDAP) the global leader in High Intensity Focused Ultrasound treatment of prostate cancer announces the launch of Ablatherm-HIFU services at Hospital Privado da Boavista, Porto, Portugal, the first HIFU treatment center in Portugal. Boavista Hospital will be using the Ablatherm-HIFU device under EDAP's innovative fixed installation Revenue-Per-Procedure (RPP) model. - Researchers Uncover How Prostate Cancer Cells Defy Death
New findings about how prostate cancer cells are able to resist hormone treatment and defy death may lead to more effective drug treatments, according to researchers from Wake Forest University School of Medicine and colleagues.
|